Wacker Chemie Ag · XETR:WCH
Wacker Chemie — Investor Day (June 2021)
33 slides from Wacker Chemie's investor day presentation, Jun 24, 2021
Slide 1: WACKER Virtual CMD Series: BIOSOLUTIONS and R&D
CREATING TOMORROW`S SOLUTIONS WACKER Virtual CMD Series: BIOSOLUTIONS and R&D Wacker Chemie AG, June 24, 2021 Ticker: WCH © Wacker Chemie AG www.wacker.com Virtual CMD Series: BIOSOLUTIONS and R&D, June 24, 2021 0
Slide 2: Disclaimer
Disclaimer The information contained in this presentation is for background purposes only and is subject to amendment, revision and updating. Certain statements and information contained in this presentation may relate to future expectations and other forward-looking statements that are based on man
Slide 3: Agenda for Today
Agenda for Today Agenda 10:00 - 11:00 AM CEST R&D / BIOSOLUTIONS Our Speakers Christian Hartel Tobias Ohler Susanne Christoph Kowitz CEO CFO Leonhartsberger Head of R&D President BIOSOLUTIONS © Wacker Chemie AG Virtual CMD Series: BIOSOLUTIONS and R&D, June 24, 2021 2
Slide 4: WACKER: Virtual CMD Series Roadmap
WACKER: Virtual CMD Series Roadmap June 2020 WACKER Strategy Update - Delivering on our 5 Targets Dec 2020 SILICONES & POLYMERS - Specialties Growth & Performance Based Substitution Today BIOSOLUTIONS and R&D - Accelerated Growth with Cutting-Edge Technologies Q4 2021 ESG & POLYSILICON - Leading CO2
Slide 5: Solid Track Record on Achieving Our 5 Targets… Ready for the Next Step
Solid Track Record on Achieving Our 5 Targets… 5 Targets Specialties Strategy Strong Group NCF on Improves Margins Lower Capital Intensity 1. CapEx – Extend Leverage 19% 39% Phase €700m €340m 2. Grow Above Chemical 14% Production €400m -4% 3. Focus Strongly on Sustainability -€40m 4. Sustain Attract
Slide 6: For Q2 2021 WACKER Expects Sales of ~€1.5bn with an EBITDA of €300-350m
Trading Update For Q2 2021 WACKER Expects Sales of ~€1.5bn with an EBITDA of €300-350m SILICONES POLYMERS Strong demand for specialties across diversified Continued demand growth in DPP1 and adhesives industries Price increases and surcharges to address Continued specialties growth supported
Slide 7: WACKER R&D – Christoph Kowitz
CREATING TOMORROW`S SOLUTIONS _WACKER R&D Christoph Kowitz Ticker: WCH © Wacker Chemie AG www.wacker.com Virtual CMD Series: BIOSOLUTIONS and R&D, June 24, 2021 6
Slide 8: Innovation is Key to WACKER’s Business Strategy
Innovation is Key to WACKER’s Business Strategy Innovation Figures R&D Spend Strong Market Presence & Technology Development in the Regions 3.3% 750 of 2020 group sales Employees spent in R&D in R&D €157m FY 2020 Globally: 23 Technical Centers and R&D Centers 4,200 1,400 Germany: Consortium for
Slide 9: Innovation Focused Across Three Pillars Driving Growth & Sustainability
Innovation Focused Across Three Pillars Driving Growth & Sustainability Applications Products Processes New applications with existing New products for existing & new New processes to increase yields technologies markets & lower emissions Silane-Modified Polymers Si Anode Battery RHYME1 Bavari
Slide 10: Advanced Adhesives Drives Strong Market Growth
Applications Advanced Adhesives Drives Strong Market Growth Silane-Modified Polymers with Excellent Performance & Substitution Drive Performance Environment Excellent adhesion & Unique α-technology elasticity for nearly all enables tin-, plasticizer-, and material combinations isocyanate-free system
Slide 11: Best-in-Class LUMISIL OCR for Optical Bonding Based on 2K Silicones
Applications Best-in-Class LUMISIL® OCR for Optical Bonding Based on 2K Silicones Market leader in UV-Curable Optical Clear Resins (OCRs) Through New Standard Attractive Growth Superior Opportunity Performance Consumer electronics, High clarity & no yellowing, autonomous driving, smart best environm
Slide 12: Silicon Containing Materials for Anodes in Lithium-ion Batteries
Products Silicon Containing Materials for Anodes in Lithium-ion Batteries Materials1 Currently Being Tested by Cell Manufacturers Feedback from OEMs and Cell Manufacturers Sets Some approaches to incl. Silicon Availability Potential Potential silicon in lithium-ion battery surface Producibility cycl
Slide 13: First-Ever Silicone Sealants & Dispersible Polymer Powders Based on Renewables
Products First-Ever Silicone Sealants & Dispersible Polymer Powders Based on Renewables ELASTOSIL® eco Silicone VINNECO® Polymer Powder Mass Balance Approach Silicone sealant produced via mass Suitable for dry-mix mortars for balance approach ETICS1 or waterproofing membranes Methanol feedstoc
Slide 14: RHYME Bavaria – Renewable Hydrogen and Methanol Bavaria
Process RHYME Bavaria – Renewable Hydrogen and Methanol Bavaria RHYME Bavaria Longterm Vision credits: vecteezy.com & freepik.com © Wacker Chemie AG Virtual CMD Series: BIOSOLUTIONS and R&D, June 24, 2021 13
Slide 15: Proprietary ESETEC E. coli Platform for Best-in-Class Rec. Protein Production
Process Proprietary ESETEC® E. coli Platform for Best-in-Class Rec. Protein Production WACKER ESETEC® E. coli Strains Platform for Diverse Biopharmaceuticals & Nutraceuticals Ever-Broadening Fast-Growing Market Applications Double-digit growth in Proteins like enzymes, dynamic pharma market hormones
Slide 16: WACKER BIOSOLUTIONS – Susanne Leonhartsberger
CREATING TOMORROW`S SOLUTIONS _WACKER BIOSOLUTIONS Susanne Leonhartsberger Ticker: WCH © Wacker Chemie AG www.wacker.com Virtual CMD Series: BIOSOLUTIONS and R&D, June 24, 2021 15
Slide 17: BIOSOLUTIONS at a Glance
BIOSOLUTIONS at a Glance Accelerated Growth in Focus on Efficiency & Cash BIOSOLUTIONS Sales BioPharma & BioIngredients in Life Science Chemicals Life Science Chemicals BioPharma FY 2020 BioPharma: Gum: GMP contract manufacturing of biologics, Food-grade polyvinyl acetate vaccines, live microbia
Slide 18: Ambition: €1bn Sales in BIOSOLUTIONS
Ambition: €1bn Sales in BIOSOLUTIONS Strategy Our Growth and Earnings Ambition Expand BioPharma capacities to support strong growth Establish WACKER as a leading mRNA & pDNA CDMO1 €1bn Sales in Grow BioIngredients product portfolio BIOSOLUTIONS Innovation and M&A to accelerate with >25% EBIT
Slide 19: WACKER’s BioIngredients and Nutraceuticals Business
WACKER’s BioIngredients and Nutraceuticals Business Fermentation-Based Solutions for a Wide Range of Applications to Meet Growing Consumer Trends Healthy Living Renewable Raw Trends Materials Antioxidants Anti-inflammatory Fermentation Broad Range of Technologies Applications Higher Bioavailability
Slide 20: WACKER is a Leading Supplier of L-Cysteine from Renewable Raw Materials
BioIngredients WACKER is a Leading Supplier of L-Cysteine from Renewable Raw Materials Broad Range of Applications Sustainable Process Free of Animal Products Flavors: savory flavors Fermentation process based on renewable raw materials Vegetarian & vegan Food: dough softening 96% less HCl
Slide 21: WACKER is a Leading Supplier of Cyclodextrins Across Many Applications
BioIngredients WACKER is a Leading Supplier of Cyclodextrins Across Many Applications Versatile Molecules from Renewable Raw Materials Plant based Enzyme production Biotransformation – Purification Cyclodextrin starch from microorganisms starch into ring- (α, β and γ) shaped molecules We Address Con
Slide 22: Megatrends Driving Activities for Portfolio Expansion & Innovation
BioIngredients Megatrends Driving Activities for Portfolio Expansion & Innovation Expanding BioIngredients Portfolio Through Innovation & Emerging Applications End Markets Market1 Trends & WACKER Solutions 7% p.a. Healthy living & heart health trend Nutraceuticals ~€500bn LDL-cholesterol reducti
Slide 23: WACKER is a Leading Microbial CDMO
BioPharma WACKER is a Leading Microbial CDMO Cutting-Edge Technologies with a Proven Track Record in a Fast-Growing Market Fast-Growing Market Outsourcing on the Rise Secretion Technology Refolding Technology Strong Track Record Cutting-Edge Technologies Live Microbial Products mRNA and pDNA © Wacke
Slide 24: Drivers for WACKER CDMO Business
BioPharma Drivers for WACKER CDMO Business Higher Outsourcing Rate1 Microbial CDMO Market2 #5 in a Fragmented Market Drives Demand for CDMOs Boehringer Lonza +10% WACKER 20% $1.8bn 15% 12% 23% Fujifilm $1.1bn WCH BioPharma: Others Trailing 5 Year 2015 2020 2025 Sales CAGR AGC Outsourcing is a tool f
Slide 25: Full-Service CDMO of Biologics with Cutting-Edge Technologies
BioPharma Full-Service CDMO of Biologics with Cutting-Edge Technologies Speed, Flexibility and Innovation in the Development & Manufacture of Biopharmaceuticals Discovery Development & Manufacturing Distribution Supply for Clinical Drug Discovery Development Manufacturing Marketing & Sales Trials Su
Slide 26: Leading Technologies for the Production of Biopharmaceuticals
BioPharma Leading Technologies for the Production of Biopharmaceuticals Unique manufacturing technology, with exceptionally Live microorganisms with therapeutic or preventive high quality & flexibility effects No cell disruption needed, high yields & lower COGS Development of scalable & full
Slide 27: Establish WACKER as a Leading mRNA & pDNA CDMO
BioPharma Establish WACKER as a Leading mRNA & pDNA CDMO Portfolio Expansion into Advanced Medicines Creates New Growth Opportunities BioPharma technologies Advanced Medicines Proteins Small peptides Antibodies Cell therapies pDNA mRNA molecules vaccines CDMO market attractiveness Technology fit WAC
Slide 28: mRNA/pDNA Technologies Enable Advanced Therapies for Multiple Indications
BioPharma mRNA/pDNA Technologies Enable Advanced Therapies for Multiple Indications mRNA CDMO Market1 & Areas Researched2 Fast Growing pDNA CDMO Market3 Infectious $240m $800m Diseases Oncology $100m $450m Others 2020 2026 Genetic Disorders Recent acquisition provides technology & large scale full
Slide 29: Creating a Leading Player with Strategic Acquisitions & Follow-On Investments
BioPharma Creating a Leading Player with Strategic Acquisitions & Follow-On Investments Global Set-Up with Cutting-Edge Technologies 2005 2008 2010 2014 2017 2018-21 2021 Jena: Jena: Jena: Halle: Halle: Amsterdam: San Diego: ProThera New lab Extension Scil Proteins Construction & SynCo acquisition A
Slide 30: BIOSOLUTIONS Strategic Focus & Roadmap
BIOSOLUTIONS Strategic Focus & Roadmap Accelerated Growth in BioPharma & BioIngredients Unique Cutting-edge technologies & strong scientific background Technology Platforms Microbial technologies with exceptionally high quality, flexibility & low COGS Customer Strong global track record: pre-c
Slide 31: Q&A Session
Q&A Session Go to Q&A www.slido.com ? # CMDJune2021 © Wacker Chemie AG Virtual CMD Series: BIOSOLUTIONS and R&D, June 24, 2021 30
Slide 32: WACKER: Virtual CMD Series Roadmap
WACKER: Virtual CMD Series Roadmap June 2020 WACKER Strategy Update - Delivering on our 5 Targets Dec 2020 SILICONES & POLYMERS - Specialties Growth & Performance Based Substitution Today BIOSOLUTIONS and R&D - Accelerated Growth with Cutting-Edge Technologies Q4 2021 ESG & POLYSILICON - Leading CO2
Slide 33: WACKER: Issuer, Contact and Additional Information
WACKER: Issuer, Contact and Additional Information Issuer and Contact Financial Calendar INVESTOR RELATIONS CONTACTS Joerg Hoffmann, CFA 08/05/21 Q2 Results 2021 Tel. +49 89 6279 1633 | joerg.hoffmann@wacker.com 10/28/21 Q3 Results 2021 Scott McCollister Q4 2021 Virtual CMD Series: ESG & POLYSILICON